Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02765256 · ClinicalTrials.gov registry record · Phase 2
Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02765256: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT02765256 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 8 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02765256, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the management of active Crohn's Disease (CD) that is refractory to conventional, immunosuppressive therapy.
Interventions
- DRUG Vancomycin
- DRUG Fluconazole
- DRUG Ciprofloxacin
- DRUG Polyethylene Glycol 3350
- DRUG Neomycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-08 |
| Est. Completion | 2018-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02765256
The ClinicalTrials.gov registry entry for NCT02765256 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Vancomycin is the first listed.
NCT02765256 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02765256 about?
NCT02765256 is a clinical study titled "Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease". To determine the effect of a novel gut microbiota-targeted therapeutic regimen (bowel lavage and antibiotics with or without an antifungal) in the management of active Crohn's Disease (CD) that is refractory to conventional, immunosuppressive therapy.
What is the current status of trial NCT02765256?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-08. Estimated completion is 2018-12.
What interventions are being tested in trial NCT02765256?
The interventions under investigation include: Vancomycin (DRUG), Fluconazole (DRUG), Ciprofloxacin (DRUG), Polyethylene Glycol 3350 (DRUG), Neomycin (DRUG).
Who is sponsoring clinical trial NCT02765256?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.